An official ATS clinical policy statement: Congenital central hypoventilation syndrome - Genetic basis, diagnosis, and management

Debra E. Weese-Mayer, Elizabeth M. Berry-Kravis, Isabella Ceccherini, Thomas G. Keens, Darius A. Loghmanee, Ha Trang

Research output: Contribution to journalArticle

Abstract

Background: Congenital central hypoventilation syndrome (CCHS) is characterized by alveolar hypoventilation and autonomic dysregulation. Purpose: (1) To demonstrate the importance of PHOX2B testing in diagnosing and treating patients with CCHS, (2) to summarize recent advances in understanding how mutations in the PHOX2B gene lead to the CCHS phenotype, and (3) to provide an update on recommendations for diagnosis and treatment of patients with CCHS. Methods: Committee members were invited on the basis of their expertise in CCH Sand asked to review the current state of the science by independently completing literature searches. Consensus on recommendations was reached by agreement among members of the Committee. Results: A review of pertinent literature allowed for the development of a document that summarizes recent advances in understanding CCHS and expert interpretation of the evidence for management of affected patients. Conclusions: A PHOX2B mutation is required to confirm the diagnosis of CCHS. Knowledge of the specific PHOX2B mutation aids in anticipating the CCHS phenotype severity. Parents of patients with CCHS should be tested for PHOX2B mutations. Maintaining a high index of suspicion in cases of unexplained alveolar hypoventilation will likely identify a higher incidence of milder cases of CCHS. Recommended management options aimed toward maximizing safety and optimizing neurocognitive outcome include: (1) biannual then annual inhospital comprehensive evaluationwith (i)physiologic studies during awake and asleep states to assess ventilatory needs during varying levels of activity and concentration, in all stages of sleep, with spontaneous breathing, and with artificial ventilation, and to assess ventilatory responsiveness to physiologic challenges while awake and asleep, (ii) 72-hour Holter monitoring, (iii) echocardiogram, (iv) evaluation of ANS dysregulation across all organ systems affected by the ANS, and (v) formal neurocognitive assessment; (2) barium enema or manometry and/or full thickness rectal biopsy for patients with a history of constipation; and (3) imaging for neural crest tumors in individuals at greatest risk based on PHOX2B mutation.

Original languageEnglish
Pages (from-to)626-644
Number of pages19
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume181
Issue number6
DOIs
Publication statusPublished - Mar 15 2010

Fingerprint

Mutation
Committee Membership
Hypoventilation
Phenotype
Congenital central hypoventilation syndrome
Ambulatory Electrocardiography
Sleep Stages
Manometry
Constipation
Consensus
Respiration
Parents
Biopsy
Safety
Incidence
Genes
Therapeutics

Keywords

  • Autonomic dysregulation
  • Respiratory control

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

An official ATS clinical policy statement : Congenital central hypoventilation syndrome - Genetic basis, diagnosis, and management. / Weese-Mayer, Debra E.; Berry-Kravis, Elizabeth M.; Ceccherini, Isabella; Keens, Thomas G.; Loghmanee, Darius A.; Trang, Ha.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 181, No. 6, 15.03.2010, p. 626-644.

Research output: Contribution to journalArticle

Weese-Mayer, Debra E. ; Berry-Kravis, Elizabeth M. ; Ceccherini, Isabella ; Keens, Thomas G. ; Loghmanee, Darius A. ; Trang, Ha. / An official ATS clinical policy statement : Congenital central hypoventilation syndrome - Genetic basis, diagnosis, and management. In: American Journal of Respiratory and Critical Care Medicine. 2010 ; Vol. 181, No. 6. pp. 626-644.
@article{da390a531a7b42a7a33cbe3d9b4d8839,
title = "An official ATS clinical policy statement: Congenital central hypoventilation syndrome - Genetic basis, diagnosis, and management",
abstract = "Background: Congenital central hypoventilation syndrome (CCHS) is characterized by alveolar hypoventilation and autonomic dysregulation. Purpose: (1) To demonstrate the importance of PHOX2B testing in diagnosing and treating patients with CCHS, (2) to summarize recent advances in understanding how mutations in the PHOX2B gene lead to the CCHS phenotype, and (3) to provide an update on recommendations for diagnosis and treatment of patients with CCHS. Methods: Committee members were invited on the basis of their expertise in CCH Sand asked to review the current state of the science by independently completing literature searches. Consensus on recommendations was reached by agreement among members of the Committee. Results: A review of pertinent literature allowed for the development of a document that summarizes recent advances in understanding CCHS and expert interpretation of the evidence for management of affected patients. Conclusions: A PHOX2B mutation is required to confirm the diagnosis of CCHS. Knowledge of the specific PHOX2B mutation aids in anticipating the CCHS phenotype severity. Parents of patients with CCHS should be tested for PHOX2B mutations. Maintaining a high index of suspicion in cases of unexplained alveolar hypoventilation will likely identify a higher incidence of milder cases of CCHS. Recommended management options aimed toward maximizing safety and optimizing neurocognitive outcome include: (1) biannual then annual inhospital comprehensive evaluationwith (i)physiologic studies during awake and asleep states to assess ventilatory needs during varying levels of activity and concentration, in all stages of sleep, with spontaneous breathing, and with artificial ventilation, and to assess ventilatory responsiveness to physiologic challenges while awake and asleep, (ii) 72-hour Holter monitoring, (iii) echocardiogram, (iv) evaluation of ANS dysregulation across all organ systems affected by the ANS, and (v) formal neurocognitive assessment; (2) barium enema or manometry and/or full thickness rectal biopsy for patients with a history of constipation; and (3) imaging for neural crest tumors in individuals at greatest risk based on PHOX2B mutation.",
keywords = "Autonomic dysregulation, Respiratory control",
author = "Weese-Mayer, {Debra E.} and Berry-Kravis, {Elizabeth M.} and Isabella Ceccherini and Keens, {Thomas G.} and Loghmanee, {Darius A.} and Ha Trang",
year = "2010",
month = "3",
day = "15",
doi = "10.1164/rccm.200807-1069ST",
language = "English",
volume = "181",
pages = "626--644",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society - AJRCCM",
number = "6",

}

TY - JOUR

T1 - An official ATS clinical policy statement

T2 - Congenital central hypoventilation syndrome - Genetic basis, diagnosis, and management

AU - Weese-Mayer, Debra E.

AU - Berry-Kravis, Elizabeth M.

AU - Ceccherini, Isabella

AU - Keens, Thomas G.

AU - Loghmanee, Darius A.

AU - Trang, Ha

PY - 2010/3/15

Y1 - 2010/3/15

N2 - Background: Congenital central hypoventilation syndrome (CCHS) is characterized by alveolar hypoventilation and autonomic dysregulation. Purpose: (1) To demonstrate the importance of PHOX2B testing in diagnosing and treating patients with CCHS, (2) to summarize recent advances in understanding how mutations in the PHOX2B gene lead to the CCHS phenotype, and (3) to provide an update on recommendations for diagnosis and treatment of patients with CCHS. Methods: Committee members were invited on the basis of their expertise in CCH Sand asked to review the current state of the science by independently completing literature searches. Consensus on recommendations was reached by agreement among members of the Committee. Results: A review of pertinent literature allowed for the development of a document that summarizes recent advances in understanding CCHS and expert interpretation of the evidence for management of affected patients. Conclusions: A PHOX2B mutation is required to confirm the diagnosis of CCHS. Knowledge of the specific PHOX2B mutation aids in anticipating the CCHS phenotype severity. Parents of patients with CCHS should be tested for PHOX2B mutations. Maintaining a high index of suspicion in cases of unexplained alveolar hypoventilation will likely identify a higher incidence of milder cases of CCHS. Recommended management options aimed toward maximizing safety and optimizing neurocognitive outcome include: (1) biannual then annual inhospital comprehensive evaluationwith (i)physiologic studies during awake and asleep states to assess ventilatory needs during varying levels of activity and concentration, in all stages of sleep, with spontaneous breathing, and with artificial ventilation, and to assess ventilatory responsiveness to physiologic challenges while awake and asleep, (ii) 72-hour Holter monitoring, (iii) echocardiogram, (iv) evaluation of ANS dysregulation across all organ systems affected by the ANS, and (v) formal neurocognitive assessment; (2) barium enema or manometry and/or full thickness rectal biopsy for patients with a history of constipation; and (3) imaging for neural crest tumors in individuals at greatest risk based on PHOX2B mutation.

AB - Background: Congenital central hypoventilation syndrome (CCHS) is characterized by alveolar hypoventilation and autonomic dysregulation. Purpose: (1) To demonstrate the importance of PHOX2B testing in diagnosing and treating patients with CCHS, (2) to summarize recent advances in understanding how mutations in the PHOX2B gene lead to the CCHS phenotype, and (3) to provide an update on recommendations for diagnosis and treatment of patients with CCHS. Methods: Committee members were invited on the basis of their expertise in CCH Sand asked to review the current state of the science by independently completing literature searches. Consensus on recommendations was reached by agreement among members of the Committee. Results: A review of pertinent literature allowed for the development of a document that summarizes recent advances in understanding CCHS and expert interpretation of the evidence for management of affected patients. Conclusions: A PHOX2B mutation is required to confirm the diagnosis of CCHS. Knowledge of the specific PHOX2B mutation aids in anticipating the CCHS phenotype severity. Parents of patients with CCHS should be tested for PHOX2B mutations. Maintaining a high index of suspicion in cases of unexplained alveolar hypoventilation will likely identify a higher incidence of milder cases of CCHS. Recommended management options aimed toward maximizing safety and optimizing neurocognitive outcome include: (1) biannual then annual inhospital comprehensive evaluationwith (i)physiologic studies during awake and asleep states to assess ventilatory needs during varying levels of activity and concentration, in all stages of sleep, with spontaneous breathing, and with artificial ventilation, and to assess ventilatory responsiveness to physiologic challenges while awake and asleep, (ii) 72-hour Holter monitoring, (iii) echocardiogram, (iv) evaluation of ANS dysregulation across all organ systems affected by the ANS, and (v) formal neurocognitive assessment; (2) barium enema or manometry and/or full thickness rectal biopsy for patients with a history of constipation; and (3) imaging for neural crest tumors in individuals at greatest risk based on PHOX2B mutation.

KW - Autonomic dysregulation

KW - Respiratory control

UR - http://www.scopus.com/inward/record.url?scp=77749322547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749322547&partnerID=8YFLogxK

U2 - 10.1164/rccm.200807-1069ST

DO - 10.1164/rccm.200807-1069ST

M3 - Article

C2 - 20208042

AN - SCOPUS:77749322547

VL - 181

SP - 626

EP - 644

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -